drugset / Trial / NCT00826878
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as well as overall response rate of tivozanib (AV-951) administration in NSCLC.
Timeline
- Start
- 2009-01
- Primary completion
- 2011-03
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivozanib | Small molecule | 1 mg | Oral |
| Subject | Tivozanib | Small molecule | 1.5 mg | Oral |